Glucose-dependent insulinotropic peptide (GIP) is an incretin peptide secreted by intestinal K cells that stimulates insulin secretion in a glucosedependent manner. It is secreted as an active, intact 42-amino acid peptide GIP 1-42 , which is rapidly degraded by dipeptidyl peptidase 4 to GIP 3-42 , which is inactive. There is currently no described monoclonal antibody-based sandwich immunoassay to quantify concentrations of GIP 1-42 , the active form of the peptide.
BACKGROUND:
Glucose-dependent insulinotropic peptide (GIP) is an incretin peptide secreted by intestinal K cells that stimulates insulin secretion in a glucosedependent manner. It is secreted as an active, intact 42-amino acid peptide GIP , which is rapidly degraded by dipeptidyl peptidase 4 to GIP , which is inactive. There is currently no described monoclonal antibody-based sandwich immunoassay to quantify concentrations of GIP , the active form of the peptide.
METHODS:
To create a sandwich ELISA for GIP , we generated a monoclonal antibody specific for the intact N-terminus of the peptide, which was further optimized to increase its affinity. We used this antibody as a conjugate antibody in a sandwich ELISA and paired it with an anti-total GIP capture monoclonal antibody to create a dual monoclonal sandwich ELISA for GIP .
RESULTS:
The sandwich ELISA was highly specific for GIP and did not recognize GIP . The ELISA demonstrated a broad dynamic range and a lower limit of quantification of 5 ng/L. Using the ELISA, we were able to show that GIP concentrations in healthy volunteers increased dramatically in the postprandial state compared to the fasting state. GIP values were correlated with total GIP values overall; however, there was substantial interindividual variation.
CONCLUSIONS:
The use of an N-terminal-specific monoclonal antibody in a sandwich ELISA format provides a robust and convenient method for measuring concentrations of GIP , the active form of the incretin hormone. This ELISA should help to improve our understanding of the role of GIP in regulating glucose-dependent insulin secretion.
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Glucose-dependent insulinotropic peptide (GIP) is an incretin hormone secreted by intestinal K cells in response to dietary intake of fat and carbohydrate (1) (2) (3) . Together with glucagon-like peptide-1 (GLP-1), which is secreted from intestinal L cells, GIP plays a major role in stimulating glucose-induced insulin secretion (4, 5 ) . Following ingestion of fat and carbohydrate, GIP is secreted into the plasma as an intact, active 42 amino acid peptide (GIP ), which augments glucose-induced insulin secretion from pancreatic ␤ cells (1-3 ) . The circulating half-life of GIP , however, is relatively short because it is cleaved in the circulation by dipeptidyl peptidase 4 (DPP4) at its N-terminal alanine residue to give rise to GIP , which is inactive (6 -8 ) .
GIP 1-42 plays a critical role in the incretin effect (1) (2) (3) . It is believed that GIP 1-42 secretion by K cells of the small intestine in response to an oral glucose load may partly account for the increased insulin secretion observed compared to what occurs when a comparable glucose load is delivered intravenously (9 ) . There have also been suggestions that GIP 1-42 may improve ␤-cell survival and regulate ␤-cell viability and antiapoptotic effects (10 -14 ) . Because of the recognized crucial role of GIP in augmenting glucose-induced insulin secretion, there have been efforts to develop robust immunoassays to measure GIP . Unfortunately, because GIP 1-42 differs from the inactive form of the hormone, GIP , by the loss of only 2 amino acids at its N-terminus, it has proved difficult to develop monoclonal antibodies selective for GIP . As a result, existing ELISAs measure both GIP and GIP and thus give an indication of total GIP concentrations (8, 15, 16 ) , whereas a previously described RIA for GIP 1-42 used a polyclonal antibody (8 ) .
LC-MS assays specific for GIP have been described, but these assays have relied on either direct LC-MS analyses or the use of immunoprecipitation of total GIP followed by LC-MS quantification of GIP (8, 15, 16 ) . Although these assays have been shown to be both accurate and precise, their complexity and expense, and the high level of operator expertise required each time the assay is performed, have prevented their implementation into most laboratories. In addition, low concentrations of GIP observed during the fasting state (Յ20 ng/L) have made quantification a challenge for these assays (8, 15, 16 ) . To develop a highly specific and robust immunoassay for active GIP, we generated a monoclonal antibody that specifically targeted the N-terminus of GIP . Afterward, in vitro-directed evolution was applied to improve the affinity of the antibody while maintaining specificity for GIP . We then paired this monoclonal antibody with an anti-total GIP monoclonal antibody to develop a dual monoclonal sandwich ELISA that specifically measures GIP .
Materials and Methods

SAMPLES AND REAGENTS
Blood samples from 16 healthy volunteers were collected in P800 tubes (Becton Dickinson) containing EDTA, aprotinin, and DPP4 inhibitor. The degradation of GIP by DPP4 is not as rapid as for GLP-1, but it is still appreciable; hence the inclusion of the DPP4 inhibitor. After plasma was separated from cells, plasma samples were stored at Ϫ70°C before analysis of GIP concentrations. Blood samples were collected from volunteers under fasting conditions and at specific time points after they consumed a mixed meal challenge consisting of approximately 400 fat calories, 400 carbohydrate calories, and 100 protein calories. Synthesized GIP and GIP 3-42 peptides were purchased from Ana Spec. Anti-total GIP monoclonal antibody was purchased from Millipore. The exact binding region of this antibody is unknown, and it recognizes both GIP and GIP . We measured total GIP concentrations using a sandwich ELISA kit (Millipore). This total GIP ELISA uses the same antitotal GIP monoclonal antibody described above as the capture antibody and rabbit polyclonal anti-total GIP antibody as the detection antibody. The manufacturer states that this kit is specific for GIP and does not recognize GLP-1, GLP-2, or glucagon.
Anti-GIP antibody generation and affinity maturation. The primary amino acid sequence of GIP is YAEG TFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKH NITQ and differs from that of GIP only by tyrosine and alanine residues at the N-terminus. To generate a monoclonal antibody specific for this N-terminus, we obtained anti-GIP hybridoma clones after fusing splenocytes from mice immunized with a peptide corresponding to the first 6 residues of human GIP conjugated to keyhole limpet hemocyanin. Next, IgGs from individual clones were screened for reactivity to both GIP and GIP . An anti-GIP 1-42 -specific antibody was selected and optimized by using yeast cell surface display (17 ) . We extracted mRNA and amplified the Ig heavy chain variable region (VH) and Ig light chain variable region (VL) genes from cDNA using a mouse Ig primer set, and determined sequences after insertion into a TA TOPO (vaccinia DNA topoisomerase I) cloning vector (Invitrogen). The wild-type single-chain fragment variable (scFv) gene, in which the antigen-specific VH and VL domains are linked into a single polypeptide, was created by single overlap extension-PCR and ligated into a display vector after digestion with SfiI restriction enzyme. Spiked mutagenesis with degenerate oligonucleotides was used for saturation mutagenesis of the VH and VL complementarity-determining regions (CDR). Individual CDR libraries were constructed by recombining the mutated scFv DNA pool into display vector digested with SfiI after cotransformation into EBY100 yeast (a kind gift from Dr. Dane Wittrup, Massachusetts Institute of Technology) by using lithium acetate as described (18, 19 ) and propagated in synthetic dextrose casamino acid media at 30°C with shaking. The scFv expression was induced by transferring midlog growth cells into synthetic galactose casamino acid media (2% galactose) and grown at 20°C for 12-24 h with shaking. An overrepresentation of each CDR library or sort output from a previous round of selection was incubated with GIP 1-42 -biotin peptide (CPC Scientific) and anti-V5 monoclonal antibody (1 mg/L) (Invitrogen) in selection buffer (PBS, pH 7.4, 0.5% BSA) at 25°C for 30 min before transfer to ice and washing with cold selection buffer. Bound antigen was detected by using streptavidin-R-phycoerythrin (Invitrogen) at a 1:200 dilution, and binding was normalized to the amount of scFv expression by using Alexa Fluor 488 goat antimouse antibody (Invitrogen) at a 1:100 dilution. Clones of interest were enriched using fluorescence-assisted cell sorting on a FACSAria cell sorter (BD Biosciences). Individual clones from CDR libraries with improved binding were sequenced.
A combinatorial library combining the CDR regions of clones from the individual libraries with improved binding was constructed by single overlap extension-PCR, and subjected to further rounds of selection with increased stringency. Individual combinatorial clones were sequenced, and the relative binding affinity determined after antigen titration (20, 21 ) . The resulting VH and VL genes were ligated into separate murine expression vectors, respectively, to create a final optimized variant, which was purified by protein A after large-scale transient transfection using HEK (human embryonic kidney) 293 cells.
BIACORE ANALYSIS
Kinetic analysis and binding specificity of the anti-GIP 1-42 specific antibody were determined by use of a Biacore T100 instrument. A Series S Sensor Chip CM5 (Biacore, BR-1006 -68) with approximately 6000 response units of goat antimouse capture antibody (1050 -01; Southern Biotech) covalently attached was used to capture approximately 1500 response units of IgG diluted to 10 mg/L in running buffer (HEPES buffered saline containing 3 mmol/L EDTA and 0.05% Tween, HBS-EP, Biacore BR-1006 -69). Increasing concentrations of GIP were injected for 5 min at a flow of 30 L/min followed by a 10-min dissociation phase. The surfaces were regenerated following each dissociation phase with two 15-L injections of glycine-HCl, pH 1.5, at a flow rate of 100 L/min. Kinetic constants were determined using the T100 Evaluation software. Specificity for GIP was tested by injections of GIP 3-42 peptide under the described assay conditions.
GIP 1-42 ELISA
After the final purification process, a dual monoclonal GIP MesoScale Discovery (MSD) ELISA was constructed using the N-terminal-specific anti GIP monoclonal antibody and the anti-total GIP monoclonal antibody. Standard MSD 96-well plates were incubated for 1 h with 50 L of anti-total GIP antibody (5 mg/L). Afterward, wells were aspirated and washed 3 times with TBST (Tris buffered saline containing 10 mmol/L Tris pH 7.40, 150 mmol/L NaCl with 1 mL Tween 20/L). Wells were blocked with 200 L of TBScasein (Thermo Fisher). Next, 50 L of GIP 1-42 calibrators (varying concentrations of GIP protein in assay buffer consisting of 50 mmol/L HEPES, pH 7.40, 150 mmol/L NaCl, 10 mL/L Triton X-100, 5 mmol/L EDTA, and 5 mmol/L EGTA) were added to the wells to generate a calibration curve. Plasma samples were diluted 1:4 in assay buffer and added to their respective wells, and the ELISA plate was incubated for 1.5 h at room temperature. Following aspiration, wells were washed 3 times with TBST, and 50 L of conjugate antibody (biotin-labeled N-terminal anti-GIP 1-42 specific antibody, 1 mg/L) were added to the wells for a 1-h incubation at room temperature. After aspiration, wells were washed 3 times with TBST, followed by the addition of 50 L of 1:5000 diluted streptavidinruthenium conjugate (Sulfo-Tag, MSD) for a 1-h incubation at room temperature. After the final aspiration, wells were washed 3 times with TBST, 150 L of 2ϫ MSD read buffer were added to the wells, and plates were developed using an MSD reader, which recorded ruthenium electrochemiluminescence.
DATA ANALYSIS
MSD software and SigmaPlot version 8.0 were used for fitting ELISA calibration curves. Data were plotted and analyzed with Fig. P (version 2.98, Biosoft) . In each case, a P value Յ0.05 was considered to indicate statistical significance.
Results
We first obtained an anti-GIP 1-42 monoclonal antibody by immunizing mice with a peptide corresponding to the first 6 residues of human GIP conjugated to keyhole limpet hemocyanin. Initial Biacore analysis of this parental antibody (Fig. 1A) indicated that although it was promising, its affinity was likely not suitable for our ultimate goal. The parental antibody did, however, demonstrate specificity for GIP vs GIP (Fig. 1B) . To improve the affinity of the antibody, the VH and VL genes were obtained from the parental hybridoma cell line, and mutations were introduced into the CDRs.
Three rounds of selection with decreasing concentrations of GIP were performed, and sequences of individual variants with improved binding were determined. A combinatorial library, in which the CDR regions of clones from the individual CDR libraries with improved binding were combined, was constructed and subjected to further rounds of selection with increased stringency to identify additive or synergistic mutational pairings. Individual combinatorial clones were sequenced, and binding characteristics were determined. Biacore analysis (Fig. 1C) indicated that the optimized antibody had much improved affinity for GIP . Importantly, the optimized antibody was also specific for GIP and did not recognize GIP (Fig.  1D) . Table 1 summarizes the characteristics of the parental and optimized antibodies and demonstrates that the optimized anti-GIP 1-42 -specific antibody resulted in a Ͼ100-fold improvement in the dissociation rate and 10-fold improvement in overall affinity for GIP compared to the parental antibody.
This optimized antibody, together with an anti-total GIP monoclonal antibody, was then investigated for pairing in a sandwich ELISA. The optimal pairing was found to be anti-total GIP antibody as the capture antibody and anti-N-terminal specific GIP antibody as the conjugate antibody. Fig. 2 shows a typical calibration curve obtained with this ELISA orientation, in which GIP 1-42 peptide was prepared at a concentration of 1 g/L and serially diluted to create a calibration curve. Based on a 3-SD evaluation of the zero calibrator, the limit of detection of the ELISA was determined to be 1 ng/L. The lower limit of quantification was determined to be 5 ng/L, and the ana-lyte measurement range of the assay was determined to be 5 ng/L to 4000 ng/L.
The sandwich ELISA was specific for GIP and did not recognize GIP (Fig. 2) . Specificity of the ELISA for other members of the peptide superfamily was also tested by using glucagon, GLP-1, GLP-2, secretin, and vasoactive intestinal peptide, each at concentrations up to 10 g/L. No cross-reactivity was observed with any of these other peptides, further suggesting that the ELISA was specific for GIP . ELISA dilution curves for the synthetic standard and actual human plasma samples were determined to be parallel, and the ELISA demonstrated acceptable dilutional linearity. When observed vs expected results were compared for the dilution studies performed, the r value was 0.99 and the regression equation was: y ϭ 1.17x-4.71. (A), The parental anti-GIP 1-42 hybridoma clone was analyzed by using Biacore technology, with serial 3-fold dilutions of GIP antigen, starting at a concentration of 90 nmol/L. (B), Biacore analysis of the specificity of the parental anti-GIP 1-42 monoclonal antibody was performed by using either 100 nmol/L GIP or 100 nmol/L GIP . (C), The optimized anti-GIP 1-42 variant was analyzed by using Biacore technology, with serial 3-fold dilutions of GIP antigen, starting at a concentration of 90 nmol/L. (D), Biacore analysis of the specificity of the optimized anti-GIP 1-42 monoclonal antibody was performed by using either 100 nmol/L GIP or 100 nmol/L GIP 3-42 . We next evaluated the ELISA using human plasma samples to assess overall robustness. Freeze-thaw stability was evaluated by testing 4 different plasma samples. Results showed acceptable freeze-thaw stability with 80%-120% recovery after 5 freeze-thaw cycles. Individual results for freeze-thaw cycles were as follows: sample A, 23, 25, 24, 24, and 23 ng/L, respectively; sample B, 173, 171, 168, 158, and 153 ng/L, respectively; sample C, 470, 486, 477, 459, and 451 ng/L, respectively; and sample D, 738, 790, 740, 737, and 747 ng/L, respectively. We assessed precision of the ELISA using human plasma samples containing 24, 360, and 754 ng/L of endogenous GIP . Intraassay (n ϭ 20) imprecision results (CVs) were 3.3%, 3.1%, and 3.5%, respectively. Interassay imprecision was also determined by having 2 different operators analyze the above samples in quadruplicate on each of 3 different days. Interassay (n ϭ 24) imprecision results (CVs) were 11.5%, 8.7%, and 6.1%, respectively.
To assess recovery, GIP 1-42 peptide was added to pooled fasting human plasma (containing 10 ng/L of endogenous GIP ), at concentrations of 500, 250, and 125 ng/L, and samples were analyzed using the ELISA. Mean (SD) results were 592 (43) ng/L, 287 (28) ng/L, and 139 (8) ng/L, indicating 80%-120% recovery at all concentrations of GIP 1-42 tested.
We next used our assay to measure GIP 1-42 concentrations following a mixed meal test in healthy individuals. To do this, 16 healthy volunteers had blood drawn at 0800 following an overnight fast. Study participants were fed a mixed meal breakfast and had their blood drawn 1 and 2 h afterward. GIP 1-42 increased dramatically (Fig.  3A) in the postprandial state compared to the fasting state. At baseline in the fasting state, the median plasma GIP concentration was 18 ng/L with a 25%-75% range of 14 -29 ng/L. At 1 and 2-h postprandial time points, GIP 1-42 concentrations increased dramatically (median 552 ng/L, 25%-75% range 439 -922 ng/L; and median 470 ng/L, 25%-75% range 278 -644 ng/L), respectively (P Ͻ 0.001 compared to fasting for both postprandial time points). Total GIP concentrations were also measured and were also observed to increase dramatically when the study participants went from a fasted to fed state. At baseline in the fasting state, the median total GIP concentration was 33 ng/L with a 25%-75% range of 20 -62 ng/L. At 1 and 2-h postprandial time points, total GIP concentrations increased dramatically (median 766 ng/L, 25%-75% range 594 -1195 ng/L; and median 773 ng/L, 25%-75% range 501-965 ng/L, respectively (P Ͻ 0.001 compared to fasting for both postprandial time points).
We next examined the correlation between total GIP and GIP (Fig. 3B) . During the fasted state, GIP values were modestly but not significantly correlated with total GIP values (r ϭ 0.42; P ϭ 0.09). In the postprandial state, GIP 1-42 concentrations were more highly correlated with total GIP concentrations (r ϭ 0.93; P Ͻ 0.001). However, the ratio of GIP to total GIP was not the same in all study participants (Fig. 3B) , suggesting large interindividual variability in the relative concentrations of GIP to total GIP in the fasting and postprandial states. In the fasting state, the range of the ratios of total GIP/GIP 1-42 were 0.51-4.62. At the 1-h postprandial time point, the range of the ratios was 0.96 -1.90, and at the 2-h postprandial time point, the range of ratios was 0.76 -3.00.
Discussion
To develop a sandwich ELISA for measuring GIP 1-42 , we generated a first-inclass monoclonal antibody targeting the N-terminus of the incretin peptide. Although this parental antibody possessed the required specificity, it had a dissociation rate that would ultimately limit the assay limit of quantification. The recent advent of in vitro display technologies (22) (23) (24) provided us the flexibility to use CDR saturation mutagenesis to increase its affinity. The optimized version of the antibody had a 100-fold improvement in the dissociation rate for GIP peptide compared to the parental antibody. At the same time, specificity for GIP was maintained after optimization, and no binding was observed to GIP .
We were then able to use this antibody to build a dual monoclonal sandwich ELISA for GIP and show that the sandwich ELISA was capable of specifically measuring GIP concentrations. This work builds upon previously reported assays for GIP 1-42 (8, 15, 16 ) . Compared to previously reported assays, however, which are LC-MS-based or rely on the use of a polyclonal antibody in an RIA format (8, 15, 16 ) , our approach uses a monoclonal antibody specific for the N-terminus of GIP in a sandwich format to measure only active GIP. Using this assay, we were able to demonstrate that healthy individuals show dramatic increases in GIP in the postprandial state compared to the fasting state. Although GIP concentrations were correlated overall with total GIP concentrations, there was large interindividual variation in the ratio of active GIP to total GIP. In addition, this correlation was higher in the fed state than the fasted state, possibly due to the lack of uniformity among the study participants during their overnight fasting.
As a result of the 2 monoclonal antibodies used, this sandwich ELISA is highly specific for GIP . From a practical standpoint, the advantage of a sandwich ELISA method over an LC-MS type method for measuring GIP concentrations is that the ELISA can be implemented in most laboratories that may have neither the complex equipment nor the highly specialized operator expertise required to routinely perform LC-MS type assays. In addition, the ELISA has the potential for higher throughput than an LC-MS assay and therefore provides the basis for the first sandwich ELISA method that can specifically measure GIP concentrations. Another advantage of this ELISA is its lower limit of quantification of 5 ng/L. This may be especially important because we observed that 50% of healthy individuals had plasma GIP concentrations Յ20 ng/L in the fasted state.
For many years, there has been great interest in the role of GIP in regulating ␤-cell function and postprandial insulin secretion (25, 26 ) . It has long been observed that the concentration of circulating insulin measured after administration of an oral glucose load is significantly greater than the circulating insulin concentration measured after a comparable amount of glucose has been administered intravenously (9 ) . Secretion of GIP from small intestine K cells following an oral glucose load is increasingly being recognized as contributing to these differences in insulin response (25, 26 ) .
Recent publications have further drawn attention to the relationship that GIP may have with the risk for developing impaired glucose tolerance and/or type 2 diabetes. Renner and coworkers created a transgenic pig with a dominant negative GIP receptor (GIPR) and demonstrated that this animal model showed a normal response to an IV glucose tolerance test, but an impaired response to an oral glucose tolerance test (27 ) . These observations were particularly interesting in light of previous studies, suggesting that an impaired response to an oral glucose tolerance test (OGTT) is associated with increased risk of developing type 2 diabetes and increased cardiovascular events (28 ) . Very recently, Saxena and colleagues demonstrated that mutations in the GIPR were associated with decreased insulin secretion and an increase in the 2-h post-OGTT glucose value of 0.15 mmol/L, and they concluded that GIPR mutations may increase the risk of developing type 2 diabetes (29 ) .
It has also become clear that GIP is the main GIP species to have activity through the GIPR. Deacon and colleagues demonstrated that GIP 3-42 bound the receptor with much less affinity than did GIP 1-42 and had no effect on cAMP accumulation (30 ) . The same researchers also demonstrated that although GIP weakly antagonized GIP 1-42 -induced cAMP accumulation and insulin output in vitro, it did not act as a physiological antagonist in vivo (30 ) .
In light of these findings, it is logical to expect that there will be an increased need for robust assays to measure GIP . By providing a relatively straightfor-ward and robust method to do so, our GIP dualmonoclonal sandwich ELISA should help increase our understanding of the role of GIP in regulating glucosedependent insulin secretion. Because our assay provides specificity for the active form of the hormone, a lower limit of quantification of 5 ng/L, and an extremely broad dynamic range, it is possible that this ELISA or one similar to it could eventually be adopted for measurement of GIP . This may be particularly helpful in evaluating GIP-based therapies or therapeutic molecules that work through the GIP pathway. 
